Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.
Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crépineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay JY, Spatz A, Emile JF, Heinrich MC, Mécheri S, Tursz T, Zitvogel L.
Borg C, et al. Among authors: emile jf.
J Clin Invest. 2004 Aug;114(3):379-88. doi: 10.1172/JCI21102.
J Clin Invest. 2004.
PMID: 15286804
Free PMC article.